Pfizer Going After AstraZeneca From A “Position Of Strength,” Read Insists
This article was originally published in The Pink Sheet Daily
Days after increasing its bid for AstraZeneca, Pfizer attempted to convince investors during its first quarter earnings call that the company doesn’t need a big merger to drive growth. Instead, such a combination would accelerate an already strong strategy, Read maintained.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.